BMI: Lichaamsgewicht bij diagnose speelt bepalende rol in overlevingskansen voor borstkankerpatiënten vooral voor vroege borstkanker stadium I en IIA.

30 december 2023: zie ook dit artikel: https://kanker-actueel.nl/overgewicht-en-obesitas-hebben-geen-negatieve-invloed-op-overleving-bij-vrouwen-met-hormoongevoelige-vormen-van-borstkanker-die-ook-cdk-46-remmers-gebruikten.html

22 september 2004: Bron: De September 2004 uitgave van the Journal of the American Medical Association's Archives of Surgery

Dikke vrouwen op moment van diagnose van borstkanker, stadium I en IIA, hebben beduidend grotere kans - 2,5 keer zo veel - te sterven aan hun borstkanker dan magere vrouwen ongeachte welke behandeling ze krijgen en gecorrigeerd naar andere invloeden als menstruatiecyclus enz. Bovendien bevestigt deze studie ook dat vrouwen met oestrogeen negatieve receptoren een grotere kans op sterven hebben dan vrouwen met oestrogeen positieve receptoren. Dit was al bekend door eerdere studies maar nu ook speelt blijkbaar het lchaamsgewicht bij diagnose ook daarin nog een extra negatieve rol voor zwaardere vrouwen t.o.v. magere vrouwen. Aldus een retrospectieve zevenjarige cohort studie onder 1376 vrouwen in de leeftijd van 24 tot 82 jaar. Ook deze studie bevestigt opnieuw de invloed van voeding en gezond eten en leven op het behandelingsproces van kanker. Lees ook ander nieuws over invloed van voeding en kanker onder voeding en onderzoek en literatuurlijst van arts-bioloog drs. E. Valstar

Hier het abstract van de studie, via de bron is het volledige artikel tegen betaling op te vragen. Zie ook deze PDF: spc4017

Onder het abstract staat een artikel over deze studie zoals dat is gepubliceerd in the Wallstreet Journal 20 september 2004.

Shelley M. Enger, PhD; Jon M. Greif, DO; Jonathan Polikoff, MD; Michael Press, MD, PhD
Arch Surg. 2004;139:954-960

. Hypothesis Body weight correlates with risk of breast cancer death.

Design A retrospective cohort study using patient medical records, electronic cancer registry data, and archived tissue specimens.

Setting A 395-bed, comprehensive community hospital.

Patients One thousand three hundred seventy-six women, aged 24 to 81 years, who were diagnosed with breast cancer between January 1, 1988, and December 31, 1995, and for whom complete medical records and adequate tissue specimens existed.

Main Outcome Measures Body weight at the time of diagnosis and patient status (ie, alive and free of breast cancer, living with breast cancer, dead of breast cancer, or dead of other cause) at the time of longest follow-up. Additional data collected, including age at diagnosis, menopausal status, tumor size, tumor grade, lymph node status, stage at diagnosis, race, estrogen-receptor (ER) status, and treatment information, were used to create multivariate Cox proportional hazards models to estimate hazard rate (HR) ratios and 95% confidence intervals (CIs) for breast cancer death. We collected ER status from the patients' medical records, when available, and supplemented the information by using immunohistochemical techniques to determine ER status from archived paraffin-embedded tumor blocks.

Results Patients were followed up for a median of 6.8 years after diagnosis. Two hundred forty-six patients died from breast cancer. Among patients with early-stage disease (I and IIA), we observed a dose-response relationship of increasing weight with increasing likelihood of dying of breast cancer. Compared with women in the lowest category of weight (<133 lb [60 kg] at diagnosis), women in the highest category (175 lb [79 kg]) experienced a 2.5-fold increased risk of dying from breast cancer (HR ratio, 2.54 [95% CI, 1.08-6.00]; trend P = .02). Women with ER-negative cancer experienced an approximately 2-fold higher risk of dying from breast cancer compared with women with ER-positive cancer, regardless of stage at diagnosis. Women in the upper 50th percentile of weight with early-stage disease and with ER-negative tumors had a nearly 5-fold increased risk of dying (HR ratio, 4.99 [95% CI, 2.17-11.48]; P for interaction = .10) compared with women in the lower 50th percentile of weight and ER-positive tumors. The results were similar for body mass index, a measure of obesity in which weight is adjusted for height.

Conclusion Body weight at diagnosis and ER status are important predictors of breast cancer death in early-stage disease.

From the Department of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena, Calif (Dr Enger); the Departments of Surgery (Dr Greif) and Oncology (Dr Polikoff), Kaiser Permanente Medical Center, San Diego, Calif; and the Department of Pathology, University of Southern California, Los Angeles (Dr Press).

22 september 2004: Hieronder een artikel uit de Wallstreet Journal over bovenstaande studie:

Bron: Wallstreet Journal

-- =DJ Body Weight Correlates With Breast-Cancer Mortality-Study --

By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES

WASHINGTON (Dow Jones)--Overweight women with early-stage breast cancer are more likely to die of the cancer than thinner women, researchers from Kaiser Permanente have found. Researchers, writing in the September edition of the Journal of the American Medical Association's Archives of Surgery, said, "We observed a...relationship of increasing weight with increasing likelihood of dying of breast cancer."

The study's authors, led by Shelley M. Enger at Kaiser's research and evaluation department in Pasadena, Calif., said they found a weak link between body weight and breast-cancer mortality at all stages of the disease, but found a stronger link in women with early stages of cancer such as Stage I and Stage IIA. This means the cancer either hasn't spread beyond the breast or that it has just started spreading to lymph nodes under the arm.

Women in the highest-weight group of 175 pounds or more had a 2.5 times greater risk of dying from breast cancer than the lowest-weight group of 133 pounds or less, according to the researchers' survey of 1,376 women diagnosed with breast cancer over a seven-year period.
The study also verified previous research that has shown women with tumors that have tested negative for estrogen receptors have a greater chance of dying than those with positive estrogen-receptor status. Women with ER negative cancer had a twofold higher risk of dying than those with ER positive cancer. Researchers found that women who weighed 151 pounds or more with ER negative breast cancer had a five times greater risk of dying than those with ER positieve tumors who weighed less than 151 pounds. Women with ER negative tumors who weighed 151 pounds or more had about a three times greater risk of dying than women less than 151 pounds. Researchers said there was only a slight increased risk of dying among heavier women with ER positive tumors than thinner women with ER positive tumors. A separate study, also published in the Archives of Surgery, found that critically injured obese trauma patients were almost six times more likely to die than non-obese trauma patients. Dr. Angela L. Neville, of Los Angeles County and the University of Southern California Medical Center, and colleagues looked at 242 trauma patients who had been admitted to an intensive-care unit in 2002. Patients were divided into two groups according to body mass index, a measure that uses body weight and height. The obese group had a BMI of 30 or higher and the non-obese group had a BMI lower than 30. Researchers found that in the obese group 13% had multiple organ failure while 3% in the non-obese group had organ failure. Among the obese patients, 32% died, while 16% of non-obese patients died. -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;

borstkanker, lichaamsgewicht, BMI, obesitas, overall overleving